Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-06-22
2011-12-06
Qazi, Sabiha (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252100, C514S255050, C514S255060, C544S120000, C544S336000
Reexamination Certificate
active
08071594
ABSTRACT:
Compounds of formula (1)wherein R1is 2-indanyl, R2is 1-methylpropyl, R3is 2-methyl-1,3-oxazol-4-yl and R4and R5together with the notrogen atom to which they are attached represents morpholino, process for their preparation, pharmaceutical compositions containing them and their use in medicine.
REFERENCES:
patent: 4596819 (1986-06-01), Nicolaides et al.
patent: 5464788 (1995-11-01), Bock et al.
patent: 5817751 (1998-10-01), Szardenings et al.
patent: 7514437 (2009-04-01), Borthwick et al.
patent: 2005/0148572 (2005-07-01), Borthwick et al.
patent: 2007/0185162 (2007-08-01), Borthwick et al.
patent: 2007/0208031 (2007-09-01), Borthwick et al.
patent: 2007/0254888 (2007-11-01), Borthwick et al.
patent: 2 326 639 (1998-12-01), None
patent: 2372740 (2002-09-01), None
patent: 9404513 (1994-03-01), None
patent: WO9937304 (1999-07-01), None
patent: WO9938844 (1999-08-01), None
patent: WO99/47549 (1999-09-01), None
patent: WO 03/053443 (2003-07-01), None
patent: WO2005/000311 (2004-10-01), None
patent: WO2006/067462 (2005-12-01), None
patent: 2006/000759 (2006-01-01), None
Grigorash, et al.,Chem. Heterocycl. Compound, 13(12): 1280-1281 (1977).
Kolasa, et al.,J. Org. Chem., 55(6): 1711-1721 (1990).
Pettibone, et al.Drug Development Research, 30(3): 129-142 (1993).
V. Stella,Pro Drugs as Novel Drug Delivery Systems, Pro Drugs: An Overview and Definition: 1-115 (1975).
Wyatt, et al.Bioorganic&Med. Chem. Letters, 11(10): 1301-1305 (2001).
Sarnyai, et al.,Psychoneuroendocrinology, 19(1): 85-117 (1994).
Akerlund, et al.,Prog. Brain Res., 139:359-365 (2002) Abstract.
Banker, et al.,Modern Pharmaceutics, 3rdEd.:596 (1996).
Testa, et al.,Pure Apple Chem., 76:907-904 (2004).
Tsataris, et al.,Drugs, 64(4):375-382 (2004) Abstract.
Vippagunta, et al.,Advanced Drug Delivery Reviews, 48:3-26 (2001).
Wolff, Manfred E.,Burger's Medicinal Chemistry, 5thEd. Part 1:975-977 (1995).
Coulter Kathryn L.
Glaxo Group Limited
Peng Tony W.
Qazi Sabiha
LandOfFree
Substituted diketopiperazines and their use as oxytocin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted diketopiperazines and their use as oxytocin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted diketopiperazines and their use as oxytocin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299813